Literature DB >> 15220518

Analysis of RB action in DNA damage checkpoint response.

Christopher N Mayhew1, Emily E Bosco, David A Solomon, Erik S Knudsen, Steven P Angus.   

Abstract

Cell cycle checkpoints play a key role in maintaining genome stability by monitoring the order and integrity of cell division events. Checkpoints induced by DNA damage function to limit the propagation of potentially deleterious mutations. The retinoblastoma tumor suppressor (RB) is a critical effector of DNA damage checkpoint function by eliciting G1-phase cell cycle arrest following genotoxic stress. Here, we describe methodologies for evaluation of three facets of RB action in the DNA damage checkpoint response: (1) transcriptional repression of E2F-regulated genes (cyclin A reporter assay); (2) induction of cell cycle arrest (Brd-U incorporation assay); and (3) inhibition of DNA double-strand break accumulation (phosphorylated-histone H2A.X detection). Together, this combination of techniques allows the evaluation of RB action in the coordinated checkpoint response to DNA damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220518     DOI: 10.1385/1-59259-811-0:003

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control.

Authors:  Ryan J Bourgo; Chellappagounder Thangavel; Adam Ertel; Jacqueline Bergseid; A Kathleen McClendon; Ludwig Wilkens; Agnieszka K Witkiewicz; Jean Y J Wang; Erik S Knudsen
Journal:  Mol Cell       Date:  2011-08-19       Impact factor: 17.970

2.  Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression.

Authors:  Wesley A Braden; Jon M Lenihan; Zhengdao Lan; K Scott Luce; William Zagorski; Emily Bosco; Michael F Reed; Jeanette G Cook; Erik S Knudsen
Journal:  Mol Cell Biol       Date:  2006-08-14       Impact factor: 4.272

3.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.

Authors:  A Kathleen McClendon; Jeffry L Dean; Dayana B Rivadeneira; Justine E Yu; Christopher A Reed; Erhe Gao; John L Farber; Thomas Force; Walter J Koch; Erik S Knudsen
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

Review 4.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

5.  RB activity alters checkpoint response and chemosensitivity in lung cancer lines.

Authors:  Michael F Reed; William A Zagorski; Erik S Knudsen
Journal:  J Surg Res       Date:  2007-07-19       Impact factor: 2.192

6.  Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.

Authors:  A Kathleen McClendon; Jeffry L Dean; Adam Ertel; Erik S Knudsen
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.